



SUGGESTED FORMULA

Formalin 10% Neutral Buffered Solution

Version number: 1.0

Volume or quantity: 100 mL

Formaldehyde Solution (37%)	27mL
Sodium Phosphate, Monobasic, USP	0.4gm
Sodium Phosphate, Dibasic, Anhydrous, USP	0.65gm
Purified Water, USP	Q.S. 100mL

Although this formulation is not prepared as a sterile preparation, passing the solution through an appropriate sterilizing filter is recommended as the solution is intended for application to an active blood supply area. Recommended for packaging: vials 5mL to 10mL or small amber bottles, intended for a single-patient use only. The solution should be prepared in a vertical airflow hood in a biological safety cabinet or barrier isolation technology.

SUGGESTED COMPOUNDING PROCEDURES

1. Calculate the required quantity of each ingredient for the total amount to be prepared
2. Accurately weight and/or measure each ingredient
3. Dissolve the sodium phosphate powders in 50mL of purified water while stirring solution until solution is clear
4. Slowly add the Formaldehyde solution to the phosphates and purified water solution, mixing well
5. Bring to volume with purified water mixing well
6. Pass solution through an appropriate 0.2µm filter
7. Package in unit-of-dose vials and label
8. Suggested Quality assessments:
 - a. Color
 - b. Clarity
 - c. Container
 - d. Label - auxiliary labels, storage, BUD, compounded medication

*Apply very sparingly to affect area

*For office or Hospital Use

*Keep out of reach of Children

*Do not inject

*For Rectal Use only

*Pregnant women should not handle

*Keep away from eyes and mucous membranes

*Poison

Store in air-tight, light resistant container, at controlled room temperature away from direct sunlight and excessive heat.

No claims are made as to the safety or efficacy of this preparation. This formulation is provided solely at the unsolicited request of the pharmacist.

Beyond-Use Dates of preparations are conservative estimates from reference books, peer-reviewed literature, and intended duration of therapy, formulation from commercially available products, organoleptic observations and current USP guidelines. Compounders may have stability studies performed by a reputable laboratory if they wish to extend the Beyond-Use Date. It is recommended that you follow USP <795> recommendations for potency testing.

Beyond-Use Date is estimated to be 6 months per Compoundingtoday.com formula #2324

Precautions:

Precautions should be taken when compounding hormones, following USP Chapter <800> standards. These may be absorbed through skin, mucous membranes and lungs. Wear appropriate personal protective equipment – and inform personnel of the risk. Mix and prepare in double-HEPA filtered or filtered/vented enclosure (hood). Pregnant women and personnel with hormone related cancers should not compound hormone preparations.

General: Precautions should be taken to prevent cross-contamination and exposure of ingredients to the compounder and contamination of the preparation by the compounder. Wear appropriate protective equipment. Use safety enclosures (hoods) when weighing and mixing.

Although much attention has been paid to ensure the accuracy of the formulation contained here, Spectrum Pharmacy Products accepts no liability for the loss or damage arising from reliance on the information. Compounding pharmacists using this formula take full responsibility for the formulations and hold Spectrum Pharmacy Products and Spectrum Chemical Mfg Corp. and its officers, directors and employees harmless for any claim arising from use of or reliance on information contained therein.

2/20 JD